Drug Profile


Alternative Names: Exanta; H 319/68

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antithrombotics; Azetidines; Benzylamines; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Deep vein thrombosis; Thromboembolism
  • Discontinued Coronary thrombosis; Shock; Thrombosis

Most Recent Events

  • 14 Feb 2006 Discontinued - Phase-III for Deep vein thrombosis in USA (SC)
  • 14 Feb 2006 Discontinued - Phase-III for Thromboembolism in USA (SC)
  • 14 Feb 2006 Discontinued - Preclinical for Coronary thrombosis in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top